Tailor-Made T-Cells take on childhood brain cancer

NCT ID NCT06193759

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent ependymoma will receive the cells after standard treatment. The main goal is to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
personalized T-cells (TSA-T) targeting tumor-specific antigens
What this could lead to
If successful, this could point toward a new treatment option for young children with hard-to-treat brain tumors, potentially reducing relapse risk.
What could go wrong
This is a very early phase 1 safety trial with only 12 participants. The personalized approach is complex and may not work for everyone; side effects from the T-cells are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR OF CNS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.